{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:08:47Z","timestamp":1793268527532,"version":"4.5.0"},"reference-count":142,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant threats, none of the available therapies have been shown to consistently reduce mortality or improve patient outcomes in clinical trials. Antibiotic combination therapy is routinely used in clinical practice; however, the preferred combination has not been defined. This narrative review focuses on evidence-based solutions for the treatment of invasive CRAB infections. We dissect the promise and perils of traditional agents used in combination, such as colistin, sulbactam, and the tetracyclines, and offer clinical pearls based on our interpretation of the available data. Next, we investigate the merits of newly developed \u03b2-lactam agents like cefiderocol and sulbactam-durlobactam, which have demonstrated contrasting results in recent randomized clinical trials. The review concludes with the authors\u2019 perspective on the evolving treatment landscape for CRAB infections, which is complicated by limited clinical data, imperfect treatment options, and a need for future clinical trials. We propose that effective treatment for CRAB infections requires a personalized approach that incorporates host factors, the site of infection, pharmacokinetic-pharmacodynamic principles, local molecular epidemiology of CRAB isolates, and careful interpretation of antibiotic susceptibility testing results. In most clinical scenarios, a dose-optimized, sulbactam-based regimen is recommended with the addition of at least one other in vitro active agent. Should sulbactam-durlobactam receive regulatory approval, recommendations will need to be re-evaluated with the most recent evidence.<\/jats:p>","DOI":"10.1093\/cid\/ciad094","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T08:04:25Z","timestamp":1682928265000},"page":"S179-S193","source":"Crossref","is-referenced-by-count":140,"title":["Navigating Available Treatment Options for Carbapenem-Resistant<i>Acinetobacter baumannii-calcoaceticus<\/i>Complex Infections"],"prefix":"10.1093","volume":"76","author":[{"given":"Ryan K","family":"Shields","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Paterson","sequence":"additional","affiliation":[{"name":"ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita D","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"issue":"3","key":"2023050108041230100_ciad094-B1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2023050108041230100_ciad094-B2","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/AAC.01464-06","article-title":"Global challenge of multidrug-resistant Acinetobacter baumannii","volume":"51","author":"Perez","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2023050108041230100_ciad094-B3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2023050108041230100_ciad094-B4","author":"Antibiotic resistance threats in the United States"},{"issue":"2","key":"2023050108041230100_ciad094-B5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2023050108041230100_ciad094-B6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"2023050108041230100_ciad094-B7","doi-asserted-by":"crossref","first-page":"e4521","DOI":"10.1093\/cid\/ciaa1464","article-title":"Changing epidemiology and decreased mortality associated with carbapenem-resistant gram-negative bacteria from 2000-2017","volume":"73","author":"Babiker","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2023050108041230100_ciad094-B8","first-page":"1803","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10325","key":"2023050108041230100_ciad094-B9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"2023050108041230100_ciad094-B10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","article-title":"Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options","volume":"11","author":"Bartal","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"5","key":"2023050108041230100_ciad094-B11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jmii.2011.12.009","article-title":"Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia","volume":"45","author":"Huang","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"key":"2023050108041230100_ciad094-B12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.micpath.2017.04.039","article-title":"Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental Acinetobacter baumannii isolates","volume":"108","author":"Bardbari","year":"2017","journal-title":"Microb Pathog"},{"issue":"42","key":"2023050108041230100_ciad094-B13","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012782","article-title":"Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection","volume":"97","author":"Burnham","year":"2018","journal-title":"Medicine (Baltimore"},{"issue":"2","key":"2023050108041230100_ciad094-B14","doi-asserted-by":"crossref","first-page":"e01495-19","DOI":"10.1128\/AAC.01495-19","article-title":"Polymyxin susceptibility testing and interpretive breakpoints: recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)","volume":"64","author":"Pogue","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050108041230100_ciad094-B15","author":"Clinical and Laboratory Standards Institute","year":"2022","journal-title":"M100: Performance Standards for Antimicrobial Susceptibility Testing"},{"key":"2023050108041230100_ciad094-B16","author":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0,","year":"2023"},{"key":"2023050108041230100_ciad094-B17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jgar.2022.08.002","article-title":"Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018)","volume":"31","author":"Seifert","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"2023050108041230100_ciad094-B18","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/phar.2607","article-title":"Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: how viable are the current options?","volume":"41","author":"O'Donnell","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"9","key":"2023050108041230100_ciad094-B19","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00781-22","article-title":"In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2023050108041230100_ciad094-B20","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s40121-021-00541-4","article-title":"Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious Diseases pharmacists","volume":"10","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"2","key":"2023050108041230100_ciad094-B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115242","article-title":"A comprehensive and contemporary \u201csnapshot\u201d of beta-lactamases in carbapenem resistant Acinetobacter baumannii","volume":"99","author":"Hujer","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"2023050108041230100_ciad094-B22","article-title":"Carbapenem-resistant Acinetobacter baumannii in U","volume":"13","author":"Iovleva","year":"2022","journal-title":"S. Hospitals: diversification of circulating lineages and antimicrobial resistance. mBio"},{"issue":"11","key":"2023050108041230100_ciad094-B23","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1128\/JCM.00619-11","article-title":"Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States","volume":"49","author":"Adams-Haduch","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"2","key":"2023050108041230100_ciad094-B24","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00356-19","article-title":"Rapid replacement of Acinetobacter baumannii strains accompanied by changes in lipooligosaccharide loci and resistance gene repertoire","volume":"10","author":"Adams","year":"2019","journal-title":"mBio"},{"issue":"7","key":"2023050108041230100_ciad094-B25","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/jac\/dks084","article-title":"Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies","volume":"67","author":"Cai","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2023050108041230100_ciad094-B26","doi-asserted-by":"crossref","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2023050108041230100_ciad094-B27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11908-019-0706-5","article-title":"Multidrug resistant Acinetobacter baumannii: resistance by any other name would still be hard to treat","volume":"21","author":"Butler","year":"2019","journal-title":"Curr Infect Dis Rep"},{"issue":"12","key":"2023050108041230100_ciad094-B28","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-014-0267-8","article-title":"Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections","volume":"74","author":"Viehman","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"2023050108041230100_ciad094-B29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2023050108041230100_ciad094-B30","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC beta-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2023050108041230100_ciad094-B31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2023050108041230100_ciad094-B32","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050108041230100_ciad094-B33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jgar.2018.11.016","article-title":"Colistin monotherapy versus colistin\/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial","volume":"17","author":"Park","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"2023050108041230100_ciad094-B34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2023050108041230100_ciad094-B35","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"issue":"2","key":"2023050108041230100_ciad094-B36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/430912","article-title":"Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials","volume":"41","author":"Bliziotis","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2023050108041230100_ciad094-B37","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/civ048","article-title":"Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance","volume":"60","author":"Qureshi","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023050108041230100_ciad094-B38","first-page":"1195","author":"Oleksiuk","year":"2014"},{"issue":"1","key":"2023050108041230100_ciad094-B39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2023050108041230100_ciad094-B40","doi-asserted-by":"crossref","first-page":"e01154-19","DOI":"10.1128\/AAC.01154-19","article-title":"In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018","volume":"63","author":"Flamm","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2023050108041230100_ciad094-B41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"9","key":"2023050108041230100_ciad094-B42","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.cmi.2020.03.035","article-title":"Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes","volume":"26","author":"Nutman","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023050108041230100_ciad094-B43","author":"Pogue","year":"2021"},{"issue":"1","key":"2023050108041230100_ciad094-B44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023050108041230100_ciad094-B45","author":"Kaye","year":"2021"},{"issue":"12","key":"2023050108041230100_ciad094-B46","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1128\/AAC.03510-14","article-title":"Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients","volume":"58","author":"Boisson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2023050108041230100_ciad094-B47","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.10-0463","article-title":"Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration","volume":"138","author":"Imberti","year":"2010","journal-title":"Chest"},{"issue":"2","key":"2023050108041230100_ciad094-B48","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1128\/AAC.02445-15","article-title":"Characterization of polymyxin B biodistribution and disposition in an animal model","volume":"60","author":"Manchandani","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050108041230100_ciad094-B49","author":"Heil","year":"2022"},{"issue":"6","key":"2023050108041230100_ciad094-B50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2014.02.012","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models","volume":"43","author":"Yokoyama","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023050108041230100_ciad094-B51","author":"Abouelhassan","year":"2022"},{"key":"2023050108041230100_ciad094-B52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.05.018","article-title":"Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii","volume":"136","author":"Jaruratanasirikul","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"2023050108041230100_ciad094-B53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00365540600951184","article-title":"High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii","volume":"39","author":"Betrosian","year":"2007","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"2023050108041230100_ciad094-B54","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"2023050108041230100_ciad094-B55","first-page":"206","article-title":"Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin\/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter","volume":"17","author":"Mosaed","year":"2018","journal-title":"Iran J Pharm Res"},{"issue":"6","key":"2023050108041230100_ciad094-B56","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"issue":"1","key":"2023050108041230100_ciad094-B57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jac\/dkx368","article-title":"Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"73","author":"Kengkla","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2023050108041230100_ciad094-B58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit Care"},{"key":"2023050108041230100_ciad094-B59","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","article-title":"Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"2023050108041230100_ciad094-B60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bjid.2012.10.029","article-title":"Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis","volume":"17","author":"Chu","year":"2013","journal-title":"Braz J Infect Dis"},{"issue":"Suppl 1","key":"2023050108041230100_ciad094-B61","first-page":"269","article-title":"Comparison of intravenous ampicillin-sulbactam plus nebulized colistin with intravenous colistin plus nebulized colistin in treatment of ventilator associated pneumonia caused by multi drug resistant Acinetobacter baumannii: randomized open label trial","volume":"18","author":"Pourheidar","year":"2019","journal-title":"Iran J Pharm Res"},{"issue":"2","key":"2023050108041230100_ciad094-B62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J Crit Care Med"},{"issue":"12","key":"2023050108041230100_ciad094-B63","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/jac\/dkt275","article-title":"TEM-1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii","volume":"68","author":"Krizova","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"231","key":"2023050108041230100_ciad094-B64","article-title":"Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii","volume":"6","author":"Kuo","year":"2015","journal-title":"Front Microbiol"},{"issue":"12","key":"2023050108041230100_ciad094-B65","doi-asserted-by":"crossref","first-page":"e01612-17","DOI":"10.1128\/AAC.01612-17","article-title":"Kinetics of sulbactam hydrolysis by beta-lactamases, and kinetics of beta-lactamase inhibition by sulbactam","volume":"61","author":"Shapiro","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2023050108041230100_ciad094-B66","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2023050108041230100_ciad094-B67","doi-asserted-by":"crossref","first-page":"e00794-17","DOI":"10.1128\/AAC.00794-17","article-title":"Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae","volume":"61","author":"Cojutti","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2023050108041230100_ciad094-B68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13054-017-1769-z","article-title":"Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study","volume":"21","author":"De Pascale","year":"2017","journal-title":"Crit Care"},{"issue":"7","key":"2023050108041230100_ciad094-B69","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2023050108041230100_ciad094-B70","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/1469-0691.12697","article-title":"Treating infections caused by carbapenemase-producing Enterobacteriaceae","volume":"20","author":"Tzouvelekis","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"2023050108041230100_ciad094-B71","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2023050108041230100_ciad094-B72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2023050108041230100_ciad094-B73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"4","key":"2023050108041230100_ciad094-B74","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s40121-021-00541-4","article-title":"Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious Diseases pharmacists","volume":"10","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"6","key":"2023050108041230100_ciad094-B75","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1128\/AAC.04987-14","article-title":"Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure","volume":"59","author":"Liou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"52","key":"2023050108041230100_ciad094-B76","article-title":"Comparison of tigecycline or cefoperazone\/sulbactam therapy for bloodstream infection due to carbapenem-resistant Acinetobacter baumannii","volume":"8","author":"Niu","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"issue":"8","key":"2023050108041230100_ciad094-B77","doi-asserted-by":"crossref","first-page":"908,","DOI":"10.1016\/j.cmi.2017.10.033","article-title":"Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Liang","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"2023050108041230100_ciad094-B78","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/CCM.0000000000000933","article-title":"Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study","volume":"43","author":"Cheng","year":"2015","journal-title":"Crit Care Med"},{"issue":"5","key":"2023050108041230100_ciad094-B79","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ijantimicag.2017.01.007","article-title":"Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model","volume":"49","author":"Cai","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"2023050108041230100_ciad094-B80","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"issue":"3","key":"2023050108041230100_ciad094-B81","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"issue":"1","key":"2023050108041230100_ciad094-B82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","article-title":"Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections","volume":"10","author":"De Pascale","year":"2020","journal-title":"Ann Intensive Care"},{"issue":"8","key":"2023050108041230100_ciad094-B83","doi-asserted-by":"crossref","first-page":"e00345-17","DOI":"10.1128\/AAC.00345-17","article-title":"Population pharmacokinetics of tigecycline in critically ill patients with severe infections","volume":"61","author":"Xie","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2023050108041230100_ciad094-B84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/microorganisms7060159","article-title":"The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence","volume":"7","author":"Fragkou","year":"2019","journal-title":"Microorganisms"},{"issue":"2","key":"2023050108041230100_ciad094-B85","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"Suppl 6)","key":"2023050108041230100_ciad094-B86","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1093\/cid\/ciu593","article-title":"Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections","volume":"59","author":"Goff","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2023050108041230100_ciad094-B87","doi-asserted-by":"crossref","first-page":"e01671-18","DOI":"10.1128\/AAC.01671-18","article-title":"Pharmacodynamics of minocycline against Acinetobacter baumannii in a rat pneumonia model","volume":"63","author":"Tarazi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2023050108041230100_ciad094-B88","doi-asserted-by":"crossref","first-page":"e01809-20","DOI":"10.1128\/AAC.01809-20","article-title":"Pharmacokinetic and pharmacodynamic profiling of minocycline for injection following a single infusion in critically ill adults in a phase iv open-label multicenter study (ACUMIN)","volume":"65","author":"Lodise","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2023050108041230100_ciad094-B89","doi-asserted-by":"crossref","first-page":"e01680-20","DOI":"10.1128\/AAC.01680-20","article-title":"Minocycline alone and in combination with polymyxin B, meropenem, and sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model","volume":"65","author":"Beganovic","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2023050108041230100_ciad094-B90","doi-asserted-by":"crossref","first-page":"e01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2023050108041230100_ciad094-B91","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2023050108041230100_ciad094-B92","doi-asserted-by":"crossref","first-page":"e00250-17","DOI":"10.1128\/AAC.00250-17","article-title":"In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2023050108041230100_ciad094-B93","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01615-10","article-title":"Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline","volume":"56","author":"Bhavnani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2023050108041230100_ciad094-B94","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jac\/dkp056","article-title":"Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model","volume":"63","author":"Koomanachai","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2023050108041230100_ciad094-B95","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"12","key":"2023050108041230100_ciad094-B96","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/10600280221085551","article-title":"Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii","volume":"56","author":"Scott","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2023050108041230100_ciad094-B97","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dkaa508","article-title":"In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii","volume":"76","author":"Noel","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2023050108041230100_ciad094-B98","doi-asserted-by":"crossref","first-page":"e02488-19","DOI":"10.1128\/AAC.02488-19","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2023050108041230100_ciad094-B99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.diagmicrobio.2019.01.016","article-title":"Biofilm prevention concentrations (BPC) of minocycline compared to polymyxin B, meropenem, and amikacin against Acinetobacter baumannii","volume":"94","author":"Beganovic","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"2023050108041230100_ciad094-B100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2023050108041230100_ciad094-B101","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/cix833","article-title":"Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis","volume":"66","author":"Tariq","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2023050108041230100_ciad094-B102","doi-asserted-by":"crossref","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New perspectives on antimicrobial agents: cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 7","key":"2023050108041230100_ciad094-B103","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In Vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2023050108041230100_ciad094-B104","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02646-20","article-title":"In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii","volume":"65","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2023050108041230100_ciad094-B105","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible gram-negative bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob Resist"},{"issue":"4","key":"2023050108041230100_ciad094-B106","doi-asserted-by":"crossref","first-page":"e00059-20","DOI":"10.1128\/AAC.00059-20","article-title":"Case commentary: the need for cefiderocol is clear, but are the supporting clinical data?","volume":"64","author":"Shields","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2023050108041230100_ciad094-B107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2023050108041230100_ciad094-B108","doi-asserted-by":"crossref","first-page":"e1261-1265","DOI":"10.1093\/cid\/ciac647","article-title":"Evolution and transmission of cefiderocol-resistant Acinetobacter baumannii during an outbreak in the burn intensive care unit","volume":"76","author":"Smoke","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2023050108041230100_ciad094-B109","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2023050108041230100_ciad094-B110","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2023050108041230100_ciad094-B111","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3390\/antibiotics11070904","article-title":"Cefiderocol for carbapenem-resistant bacteria: handle with care! A review of the real-world evidence","volume":"11","author":"Sansone","year":"2022","journal-title":"Antibiotics (Basel"},{"issue":"1","key":"2023050108041230100_ciad094-B112","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antibiotics11010003","article-title":"Cefiderocol for severe carbapenem-resistant A. baumannii pneumonia: towards the comprehension of its place in therapy","volume":"11","author":"Rando","year":"2021","journal-title":"Antibiotics (Basel"},{"issue":"5","key":"2023050108041230100_ciad094-B113","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00065-22","article-title":"In a pinch: cefiderocol for CRAB infections","volume":"66","author":"Karaba","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2023050108041230100_ciad094-B114","doi-asserted-by":"crossref","first-page":"e01221-20","DOI":"10.1128\/AAC.01221-20","article-title":"Cefiderocol resistance in Acinetobacter baumannii: Roles of beta-lactamases, siderophore receptors, and penicillin binding protein 3","volume":"64","author":"Malik","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2023050108041230100_ciad094-B115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00877-21","article-title":"Contribution of PER-type and NDM-type beta-lactamases to cefiderocol resistance in Acinetobacter baumannii","volume":"65","author":"Poirel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2023050108041230100_ciad094-B116","doi-asserted-by":"crossref","first-page":"e00559-20","DOI":"10.1128\/AAC.00559-20","article-title":"Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2023050108041230100_ciad094-B117","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac484","article-title":"Pharmacokinetic analysis and in vitro synergy evaluation of cefiderocol, sulbactam, and tigecycline in an extensively drug-resistant Acinetobacter baumannii pneumonia patient receiving continuous venovenous hemodiafiltration","volume":"9","author":"Kobic","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023050108041230100_ciad094-B118","author":"Gill"},{"issue":"11","key":"2023050108041230100_ciad094-B119","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2023050108041230100_ciad094-B120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jcph.1986","article-title":"Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects","volume":"62","author":"Kawaguchi","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"2023050108041230100_ciad094-B121","doi-asserted-by":"crossref","first-page":"e02031-18","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2023050108041230100_ciad094-B122","first-page":"17104","article-title":"is a broad-spectrum beta-lactamase inhibitor for the treatment of drug-resistant gram-negative bacteria including Acinetobacter baumannii","volume":"2017","author":"Durand-Reville","year":"2514","journal-title":"Nat Microbiol"},{"issue":"709974","key":"2023050108041230100_ciad094-B123","article-title":"Durlobactam, a new diazabicyclooctane beta-lactamase inhibitor for the treatment of acinetobacter infections in combination with sulbactam","volume":"12","author":"Shapiro","year":"2021","journal-title":"Front Microbiol"},{"key":"2023050108041230100_ciad094-B124","author":"Bhavnani","year":"2022"},{"key":"2023050108041230100_ciad094-B125","author":"Altarac"},{"issue":"4","key":"2023050108041230100_ciad094-B126","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac092","article-title":"Novel combination therapy for extensively drug-resistant Acinetobacter baumannii necrotizing pneumonia complicated by empyema: a case report","volume":"9","author":"Holger","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"2023050108041230100_ciad094-B127","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00924-21","article-title":"Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination","volume":"65","author":"Zaidan","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2023050108041230100_ciad094-B128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"2023050108041230100_ciad094-B129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","article-title":"Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial","volume":"20","author":"Niederman","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2023050108041230100_ciad094-B130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2023050108041230100_ciad094-B131","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13613-022-01068-8","article-title":"Aerosolized polymyxins for ventilator-associated pneumonia caused by extensive drug resistant gram-negative bacteria: class, dose and manner should remain the trifecta","volume":"12","author":"Rouby","year":"2022","journal-title":"Ann Intensive Care"},{"issue":"10","key":"2023050108041230100_ciad094-B132","doi-asserted-by":"crossref","first-page":"e00954-17","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2023050108041230100_ciad094-B133","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2023050108041230100_ciad094-B134","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial","volume":"21","author":"Leitner","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2023050108041230100_ciad094-B135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-022-00523-5","article-title":"Evaluation the reactivity of a peptide-based monoclonal antibody derived from OmpA with drug resistant pulsotypes of Acinetobacter baumannii as a potential therapeutic approach","volume":"21","author":"Yeganeh","year":"2022","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"10","key":"2023050108041230100_ciad094-B136","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00162-21","article-title":"Monoclonal antibody therapy against Acinetobacter baumannii","volume":"89","author":"Nielsen","year":"2021","journal-title":"Infect Immun"},{"issue":"4","key":"2023050108041230100_ciad094-B137","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/infdis\/jix315","article-title":"Monoclonal antibody protects against Acinetobacter baumannii infection by enhancing bacterial clearance and evading sepsis","volume":"216","author":"Nielsen","year":"2017","journal-title":"J Infect Dis"},{"issue":"6","key":"2023050108041230100_ciad094-B138","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QCO.0000000000000885","article-title":"Novel agents in development for multidrug-resistant gram-negative infections: potential new options facing multiple challenges","volume":"35","author":"Arya","year":"2022","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"2023050108041230100_ciad094-B139","doi-asserted-by":"crossref","first-page":"e01110-18","DOI":"10.1128\/AAC.01110-18","article-title":"New treatment options against carbapenem-resistant Acinetobacter baumannii infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2023050108041230100_ciad094-B140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/QCO.0000000000000627","article-title":"New treatment options for multiresistant gram negatives","volume":"33","author":"Paterson","year":"2020","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"2023050108041230100_ciad094-B141","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"2023050108041230100_ciad094-B142","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkaa208","article-title":"In vitro activity of sulbactam\/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii","volume":"75","author":"Seifert","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/Supplement_2\/S179\/50083709\/ciad094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/Supplement_2\/S179\/50083709\/ciad094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:42:47Z","timestamp":1701909767000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/Supplement_2\/S179\/7140356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":142,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2023,5,1]]},"published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad094","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,5,1]]}}}